Formycon AG (ETR:FYB)
29.70
-0.80 (-2.62%)
Feb 21, 2025, 5:35 PM CET
Formycon AG Employees
Formycon AG had 238 employees as of December 31, 2023. The number of employees increased by 33 or 16.10% compared to the previous year.
Employees
238
Change (1Y)
33
Growth (1Y)
16.10%
Revenue / Employee
€254,393
Profits / Employee
€267,351
Market Cap
524.41M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Siemens Healthineers AG | 72,000 |
Merck KGaA | 62,908 |
Bayer Aktiengesellschaft | 96,931 |
Fresenius SE & Co. KGaA | 193,865 |
Sartorius Aktiengesellschaft | 13,528 |
Fresenius Medical Care AG | 119,845 |
Carl Zeiss Meditec AG | 5,730 |
SCHOTT Pharma AG & Co. KGaA | 4,690 |
Formycon AG News
- 1 day ago - EQS-DD: Formycon AG: Dr. Andreas Seidl, buy - Wallstreet:Online
- 2 days ago - EQS-News: Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin - Wallstreet:Online
- 5 days ago - Formycon AG: Biosimilar Updates & Conference Call Invite - Wallstreet:Online
- 5 days ago - EQS-News: Formycon AG informs about recent developments in various biosimilar projects and invites to conference call - Wallstreet:Online
- 5 days ago - EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201 - Wallstreet:Online
- 17 days ago - EQS-News: Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea biosimilar FYB203/AHZANTIVE in the Asia-Pacific Region - Wallstreet:Online
- 4 weeks ago - EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama - Wallstreet:Online
- 5 weeks ago - EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online